StonvexLoading…
StonvexStonvexStonvexCore line items from LIN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-30 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $9.09B | $8.78B | $33.99B | $25.22B | $16.61B |
Operating Income | Not available | $2.44B | $8.92B | $6.91B | $4.54B |
Net Income | Not available | $1.86B | $6.90B | $5.37B | $3.44B |
EPS (Diluted) | $4.53 | $3.98 | $14.61 | $11.34 | $7.24 |
Total Assets | Not available | $86.31B | $86.82B | $85.99B | $86.08B |
Total Liabilities | Not available | $46.22B | $47.08B | $45.91B | $46.09B |
Cash & Equivalents | Not available | $3.96B | $5.06B | $4.51B | $4.79B |
Free Cash Flow OCF − CapEx | Not available | $898.00M | $5.09B | $3.52B | $1.84B |
Shares Outstanding | Not available | 466.32M | 472.19M | 473.50M | 474.69M |